Clinical trials: Stage I Breast Cancer
Advanced or Metastatic Breast Cancer, ER+ve Advanced or Metastatic Breast Cancer
Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients
The purpose of this study is to investigate the safety and efficacy of different doses and schedules of AZD5363, when in combination with paclitaxel, in treatment of patients with advanced or metastatic breast cancer.
- Trial name
- BEECH (NCT01625286)
- Testing
- AZD5363 when combined with weekly paclitaxel., AZD5363when combined with weekly paclitaxel.
- Where
- 41 sites in Bulgaria, Canada and 9 more
- Volunteers
- 148 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Breast Cancer
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
The purpose of this study is to determine the safety and preliminary effectiveness of ixabepilone plus lapatinib with and without capecitabine in the treatment of human epidermal growth factor receptor 2 (HER2)-positive or…
- Trial name
- NCT00634088
- Testing
- Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg, Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg, Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 13 people
- Sponsor
- R-Pharm
Breast Neoplasms, Stomach Neoplasms
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
The aim of the study is to determine the Maximum Tolerated Dose (MTD) of afatinib in combination with 3-weekly trastuzumab in HER2 overexpressing cancer and to assess the efficacy of afatinib given at the MTD dosage, with…
- Trial name
- NCT01649271
- Testing
- Herceptin, afatinib, trastuzumab
- Where
- 3 sites in France
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
Medical Oncology
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase II dose (RP2D) of BAY1161909 in combination with paclitaxel in subjects with advanced malignancies.
- Trial name
- NCT02138812
- Testing
- BAY1161909, Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 69 people
- Sponsor
- Bayer
Advanced or Metastatic Breast Cancer
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with…
- Trial name
- NCT05187832
- Testing
- AND019 PO QD
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Kind Pharmaceuticals LLC
Breast Cancer
A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
This clinical trial is evaluating AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: 1.
- Trial name
- NCT05489679
- Testing
- AC682
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Accutar Biotechnology Inc
Metastatic Breast Cancer, Colorectal Cancer
Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer
The Wnt proteins belong to a family of proteins that have been demonstrated to play a role in the formation and dissemination of tumours.
- Conditions
- Metastatic Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT02020291
- Testing
- Foxy-5
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- WntResearch AB
Neoplasms, Breast
Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer
This study will examine the inhibition of ErbB1 and ErbB2 phosphorylation and downstream mediators of tumor cell growth and survival tumor tissue in treatment-naive breast cancer patients for three dosing schedules of lapatinib.
- Trial name
- NCT00359190
- Testing
- lapatinib
- Where
- 10 sites in United States, Israel
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer, Triple Negative Breast Cancer
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
This clinical trial is an open-label, single-centre, dose escalation, phase I study designed to investigate the safety and tolerability of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Gamma Delta…
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Sarcoma, Nasopharyngeal Carcinoma
- Trial name
- NCT04107142
- Testing
- Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- CytoMed Therapeutics Pte Ltd
Tumors
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
- Trial name
- NCT00248404
- Testing
- NB1011
- Where
- 3 sites in United States, Canada
- Volunteers
- 155 people
- Sponsor
- Kiadis Pharma
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumours, Breast Cancer
A Study of IMP4297 in Patients With Advanced Solid Tumors
This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered orally once every day to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be…
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03508011
- Testing
- IMP4297
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- Impact Therapeutics, Inc.
Breast Cancer
A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
The purpose of this study is to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase II dose of ixabepilone in combination with capecitabine in Japanese participants with metastatic…
- Trial name
- NCT00568022
- Testing
- Ixabepilone, Capecitabine
- Where
- 4 sites in Japan
- Volunteers
- 9 people
- Sponsor
- R-Pharm
HER2 + Breast Cancer
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
This is a study to compare the similarity in Pharmacokinetics (PK) profile of HLX319 vs. EU-Phesgo® in patients with HER2-positive early or locally advanced breast cancer .
- Trial name
- NCT07601620
- Testing
- HLX319, EU-Phesgo®
- Volunteers
- 258 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.
RATIONALE: Plant extracted natural compounds, in an adjunct therapy position, slow the growth and reproduction of Stage IV Breast Cancer tumor cells. May help eradicate different types of cancers.
- Trial name
- NCT00910884
- Testing
- laboratory biomarker analysis, therapeutic dietary intervention
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Brabant Research
Breast Cancer
Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer
RATIONALE: Microwave thermotherapy kills tumor cells by heating them to several degrees above body temperature. PURPOSE: Randomized phase II trial to compare the effectiveness of microwave thermotherapy before surgery to that of…
- Trial name
- NCT00036998
- Testing
- conventional surgery, neoadjuvant therapy, thermal ablation therapy
- Where
- 8 sites in United States, United Kingdom
- Sponsor
- Imunon
Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
This is a multicenter, open-label, non-controlled, phase I study to investigate the tolerability and safety of ONO-4578 used in combination with standard-of-care letrozole and a CDK4/6 inhibitor (palbociclib or Abemaciclib) as…
- Conditions
- Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT06570031
- Testing
- ONO-4578, letrozole, Palbociclib
- Where
- 13 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Breast Cancer, Solid Tumor
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated…
- Trial name
- NCT05039931
- Testing
- GNC-035
- Where
- China
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumors, Breast Cancer
A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
This study will assess the safety, tolerability, and the maximum tolerated dose (MTD) of MK-2206 in combination with both trastuzumab and trastuzumab/lapatinib in participants with human epidermal growth factor receptor 2…
- Trial name
- NCT00963547
- Testing
- MK-2206, Trastuzumab, Lapatinib
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
NON-breast HER2+ Malignancies
Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer
A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies
- Trial name
- NCT03696771
- Testing
- NJH395
- Where
- 4 sites in United States, Italy and 2 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals